Digoxin: Na+/K+ ATPase Pump Inhibitor for Heart Failure and Antiviral Research

Executive Summary. Digoxin, a cardiac glycoside from APExBIO, is a potent Na+/K+ ATPase inhibitor with a molecular weight of 780.94 and a chemical formula of C₄₁H₆₄O₁₄ (product page). Its mechanism increases intracellular calcium, enhancing cardiac contractility—critical for heart failure and arrhythmia research (see related review). Digoxin shows dose-dependent inhibition of chikungunya virus (CHIKV) in human osteosarcoma (U-2 OS) and synovial fibroblast cells at 0.01–10 μM, but not in murine or mosquito cells. It exhibits high purity (>98%), as verified by HPLC and NMR, and requires protection from light and storage at 4°C. Animal models confirm its efficacy in modulating cardiac output following intravenous administration (1–1.2 mg) in congestive heart failure due to pulmonary artery constriction.

Biological Rationale

Cardiac glycosides, including digoxin, have long been integral to cardiovascular disease research, particularly in the study and management of heart failure and arrhythmias (APExBIO). Digoxin specifically targets the Na+/K+ ATPase pump, a membrane-bound enzyme essential for maintaining electrochemical gradients in excitable tissues such as myocardium (see translational review). By modulating ion transport, digoxin serves as a critical tool for dissecting excitation-contraction coupling and for evaluating the impact of altered cardiac contractility in translational and preclinical models. Its specificity, well-characterized pharmacology, and robust documentation make it a gold-standard reagent for both mechanistic and applied cardiovascular studies (contrast with practical lab guidance).

Mechanism of Action of Digoxin

Digoxin acts as a high-affinity inhibitor of the Na+/K+ ATPase pump. The inhibition increases intracellular sodium, which secondarily elevates intracellular calcium via the sodium-calcium exchanger. The increased calcium enhances myocardial contractility, which is central to its therapeutic and research value in heart failure (mechanistic review). This mechanism is well-conserved across human and many mammalian cell types. Notably, the Na+/K+-ATPase signaling pathway regulated by digoxin also intersects with cellular pathways relevant to arrhythmic events and viral replication cycles.

• Primary target: Na+/K+ ATPase pump (membrane-bound, ubiquitous in excitable tissues).
• Downstream effect: Increased intracellular Na⁺ blocks extrusion of Ca²⁺, raising cytosolic Ca²⁺ concentration.
• Functional outcome: Enhanced cardiac contractility and altered electrophysiological properties of cardiomyocytes.
• Antiviral effect: Inhibition of CHIKV is mediated by disruption of host cell ionic gradients required for viral replication in select human cell types.

Evidence & Benchmarks

• Digoxin (SKU: B7684) demonstrates >98% purity by HPLC and NMR analyses (APExBIO, Certificate of Analysis).
• In vitro, digoxin inhibits CHIKV infection in human osteosarcoma (U-2 OS), primary human synovial fibroblasts, and Vero cells in a dose-dependent manner at 0.01–10 μM (DOI:10.2146/ajhp100348).
• No antiviral activity is observed in murine or mosquito cell lines at equivalent concentrations (detailed cell specificity).
• In canine congestive heart failure models, intravenous digoxin (1–1.2 mg) reduces right atrial pressure and increases cardiac output following pulmonary artery constriction (DOI:10.2146/ajhp100348).
• Digoxin is insoluble in water and ethanol, but dissolves at ≥33.25 mg/mL in DMSO; stability is maintained when stored at 4°C and protected from light for short-term (APExBIO).
• Cardiac glycosides such as digoxin are routinely used to assess Na+/K+ ATPase function in both cardiac and non-cardiac research settings (see framework).

Applications, Limits & Misconceptions

Digoxin's primary research applications include:

• Modeling and modulation of cardiac contractility in heart failure and arrhythmia studies.
• Experimental inhibition of Na+/K+ ATPase signaling in cellular models.
• Antiviral agent in CHIKV infection models for human but not murine or insect cells.
• Tool for dissecting ionic dependencies in excitable tissue research.

Compared to prior guidance, this article clarifies cell-type specificity and storage parameters to maximize reproducibility in complex biological assays.

Common Pitfalls or Misconceptions

• Digoxin does not exhibit antiviral activity in murine or mosquito cell lines; its effect is human cell-type specific (see nuances).
• It is insoluble in water and ethanol; only DMSO yields suitable concentrations for in vitro work.
• Digoxin solutions are unstable for long-term storage, even at 4°C—always prepare fresh solutions for experimental use.
• Therapeutic protocols in clinical settings do not directly translate to in vitro or animal model dosing; always reference condition- and species-specific data.
• Na+/K+ ATPase inhibition by digoxin is not reversible by simple washout in acute settings; downstream effects can persist.

Workflow Integration & Parameters

For reliable results, prepare digoxin fresh at concentrations up to 33.25 mg/mL in DMSO (APExBIO). Store powder protected from light at 4°C. For cell-based antiviral assays, use 0.01–10 μM, monitoring for cell-type response. In cardiac contractility or ion-transport experiments, titrate concentrations according to established benchmarks for the model system. Animal studies should reference published dosing protocols—e.g., 1–1.2 mg intravenous for canine congestive heart failure models. All experimental designs should include appropriate controls for ionic changes and specificity. See our comparative review for protocol distinctions between cardiac and antiviral studies.

Conclusion & Outlook

Digoxin (SKU B7684) from APExBIO remains a cornerstone for heart failure, arrhythmia, and antiviral research due to its well-defined mechanism, high purity, and robust documentation. Its cell-type-specific antiviral activity highlights translational potential beyond cardiovascular disease. For further strategic insights, see "Digoxin as a Translational Catalyst", which contextualizes these findings for next-generation experimental design. Ongoing research will clarify its full capabilities and boundaries in both cardiac and infectious disease models.